...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone.
【24h】

Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone.

机译：仅使用超分割外束放射疗法治疗中度风险的前列腺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Intermediate-risk prostate cancer has been treated in many ways; the most effective treatment is uncertain. Hypofractionated external beam radiotherapy (HyRT) is a short and convenient alternative treatment. We report our results of HyRT in intermediate-risk patients. MATERIAL AND METHODS: Eighty two patients with intermediate-risk prostate cancer were treated with 3-dimensional conformal HyRT plans to the dose of 66 Gy/22 fractions prescribed at the isocenter without hormones. Intermediate-risk was defined as clinical stage T2b-T2c, or pre-treatment PSA between 10 and 20 ng/mL, or Gleason Score equal 7. The planning target volume consisted of the prostate plus a uniform 7 mm margin. Toxicity was prospectively graded by the Common Terminology Criteria version3. Biochemical relapse was defined as post-radiotherapy nadir PSA+2 ng/mL. RESULTS: With a median follow-up of 51 months, 5-year actuarial biochemical recurrence free survival is 95.4%. At the last follow-up visit, grade >/= 2 late gastro-intestinal and genito-urinary toxicity rates were 2% and 7%, respectively. No patient ever developed grade 4 or 5 toxicity. CONCLUSION: HyRT to a dose of 66 Gy in 22 fractions as a single treatment modality is convenient for patients and for the health care system and appears to provide similar results to other treatment choices.
机译：目的：中危前列腺癌已通过多种方式治疗;最有效的治疗方法尚不确定。次分割外束放射疗法（HyRT）是一种简便快捷的替代疗法。我们报告了中度风险患者的HyRT结果。材料与方法：对32例中危前列腺癌患者进行3D适形HyRT计划治疗，剂量为等激素点66 Gy / 22分数，无激素。中度风险定义为临床阶段T2b-T2c，或治疗前PSA在10至20 ng / mL之间，或格里森评分等于7。计划目标体积由前列腺加上均匀的7 mm边缘组成。毒性根据《通用术语标准》第3版进行了分级。生化复发定义为放疗后最低点PSA + 2 ng / mL。结果：中位随访51个月，5年精算生化无复发生存率为95.4％。在最后一次随访中，> / = 2级晚期胃肠道和生殖泌尿的毒性率分别为2％和7％。没有患者出现4级或5级毒性。结论：HyRT分为22个部分，剂量为66 Gy，是一种单一的治疗方式，对患者和卫生保健系统都很方便，并且似乎提供与其他治疗选择相似的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号